EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis.

Conclusion: Patients with EGFR+ LA-NSCLC have a significantly higher likelihood of developing brain metastasis after standard combined modality therapy, independent of their longer overall survival. This high-risk genotypic subgroup may benefit from routine surveillance with brain MRI to allow early salvage with targeted systemic- and/or radiation-therapies. PMID: 31341973 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31341973?dopt=Abstract

Source: Clinical Lung Cancer - July 27, 2019 Category: Cancer & Oncology Authors: Mitra D, Chen YH, Li R, Hermann G, Atkins K, Kozono D, Baldini EH, Aizer A, Chukwueke U, Mak RH Tags: Clin Transl Radiat Oncol Source Type: research